JAKAVI was studied in the most comprehensive clinical trial program in myelofibrosis to date1,2
COMFORT-II: Open-label, randomised, Phase III study versus BAT2,3

- "Real-world" comparator study—BAT included any single treatment or combination of treatments2,4
- 34 (47%) patients received hydroxyurea
- 49 (67%) patients received 1 or more BAT medications
- 24 (33%) patients received no medication
Primary endpoint: Proportion of patients achieving a ≥35% reduction in spleen volume from baseline at Week 48 (as measured by MRI or CT scan).2
Secondary endpoints2:
- Proportion of patients achieving a ≥35% reduction from baseline in spleen volume at Week 24
- Duration of maintenance of a ≥35% reduction in spleen volume from baseline
- Time to a reduction of ≥35% from baseline in spleen volume
- Change in bone marrow histomorphology
- Progression-free survival
- Leukaemia-free survival
- Overall survival